STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage

HORSHAM, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced an initiative aimed at expanding insurance coverage for essential treatments for conditions such as mycosis fungoides, lichen planus, alopecia areata, and cutaneous T-Cell lymphoma (CTCL), with an initial targeted focus on expanding coverage for vitiligo and atopic dermatitis, skin diseases effecting up to 3 and 16 million people in the United States respectively¹. The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.

“Our focus extends beyond merely seeking expanded insurance coverage; we're advocating for the enhancement of patient quality of life and ensuring access to essential dermatologic treatments," stated Dr. Dolev Rafaeli, Vice Chairman and Chief Executive Officer of STRATA. "By encouraging our patients to voice their needs and by proactively collaborating with policymakers, we're dedicated to guaranteeing that each person can access the medically necessary care they require.” Dr. Rafaeli continued, “We are encouraged by our initial outreach effort to a segment of our patient database and are using those results to engage with our elected officials to help these individuals and others similarly situated.”

Building on the momentum of the healthcare industry's notable achievements in re-evaluating CPT codes, the Company is focused on expanding the coverage of phototherapy treatments under codes 96920, 96921, and 96922 which are uniquely dedicated to, and are reflective in value of excimer laser procedures for small, medium and larger affected skin area. Through a comprehensive direct-to-consumer outreach initiative, the Company intends to expand on its initial outreach efforts by leveraging its vast network of over 270,000 patients to broaden patient access to medically necessary treatments and equitable reimbursement rates that accurately reflect the proven value and effectiveness of phototherapy treatments.